

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application Number : 10/733,489 Confirmation No. 7678  
Applicants : Yaron ILAN *et al.*  
Filed : December 10, 2003  
Title : REGULATION OF IMMUNE RESPONSES BY MANIPULATION  
OF INTERMEDIARY METABOLITE LEVELS  
TC/Art Unit : 1648  
Examiner: : Emily M. Le  
Docket No. : 59046.000042 (Enz-64(D1))  
Customer No. : 21967

**PETITION FOR THREE-MONTH EXTENSION OF TIME AND  
AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants respectfully request entry of the attached amendment. The Commissioner is hereby authorized to charge any fees due in connection with this correspondence to the undersigned's Deposit Account No. 50-0206.

**PETITION FOR THREE-MONTH EXTENSION OF TIME**

Applicants respectfully petition for a three-month extension of time under 37 C.F.R. § 1.136(a) for responding to the U.S. Patent and Trademark Office ("USPTO") Office Action ("Office Action") mailed in the above-captioned application ("the Application") on August 21, 2007, thereby extending the period for reply up to and including February 21, 2007. Applicants submit herewith a requisite three-month extension of time fee for a small entity in the amount of \$525.00 pursuant to 37 C.F.R. § 1.17(a). However, in the event that any additional fees are determined to be necessary by the USPTO, please charge or credit any such fees to the undersigned's **Deposit Account No. 50-0206**.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper; and

**Remarks** begin on page 5.

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims**

Claims 1-11 (Cancelled).

12. (Previously Presented) A process for treating a disease in a mammalian subject comprising administering to said subject an effective amount of an intermediary metabolite or a reagent that increases the intracellular or extracellular or serum level of a mammalian intermediary metabolite in said subject, wherein said intermediary metabolite or reagent is a glycolipid, and wherein said disease is cancer, a viral infection, or an autoimmune disease.

13. (Cancelled)

14. (Cancelled)

15. (Previously Presented) The process of claim 12, wherein said glycolipid comprises a monosaccharide ceramide.

16. (Previously Presented) The process of claim 15, wherein said monosaccharide ceramide comprises a glucosyl ceramide or galactosyl ceramide.

17. (Original) The process of claim 12, wherein said administering step is carried out by means comprising intravenous means, intramuscular means, subcutaneous means, intra-peritoneal means or oral means.

18. (Cancelled)

19. (Cancelled)

20. (Previously Presented) The process of claim 12, wherein said viral infection comprises HBV, HCV or HIV.

21. (Withdrawn) The process of claim 12, wherein said autoimmune disease comprises diabetes type I, diabetes type II, rheumatoid arthritis, Crohn's disease, arteriosclerosis and ulcerative colitis.

22. (Previously presented) The process of claim 12, wherein said reagent increases the rate of production of said glycolipid in said subject.

23. (Previously presented) The process of claim 12, wherein said reagent decreases the rate of degradation or turnover of said glycolipid in said subject.

24. (Currently amended) The process of claim 12, wherein said mammalian subject ~~comprises~~ is a human.

Claims 25-62 (Cancelled).

63. (Previously presented) The process of claim 15, wherein the viral infection is an HCV infection.

64. (Previously presented) The process of claim 16, wherein the viral infection is an HCV infection.

**REMARKS**

Claims 12, 15-17, 20-24, 63 and 64 were pending. Claim 21 stands withdrawn. It is understood that withdrawn claim 21 will be rejoined upon allowance of a linking claim. Claim 24 is currently amended. Support for the amendment can be found throughout the specification as originally filed, *inter alia*, at page 4, line 7. No new matter has been added. Upon entry of this amendment, claims 12, 15-17, 20-24, 63 and 64 will be pending in the present application. Applicants respectfully request entry of the amendment and reconsideration of the pending claims. Therefore, claims **12, 15-17, 20-24, 63 and 64** will be pending. Applicants respectfully request entry of the amendment, and reconsideration of the pending claims.

***Reply to Rejection Under 35 U.S.C. § 112, ¶ 1, Written Description***

Claims 12, 15-17, 20, 22-24 and 63-64 were rejected under 35 U.S.C. § 112, ¶ 1 as allegedly failing to comply with the written description requirement of 35 U.S.C. § 112, ¶ 1. *See* Office Action at section 4.

The Examiner states that “the claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.” *Id.* First, the Examiner states that “[t]he specification suggests the use of glycolipids to modulate the immune system to treat HCV infection, However, the specification does not contain a description of actual reduction to practice that glycolipids are effective in treating HCV infection.” *Id.* at p. 4. (emphasis added). Second, the Examiner states, “[n]or has Applicant shown that the invention was ‘ready for patenting’ by disclosing drawings demonstrating that glycolipids are effective in treating HCV infection.” *Id.* at p. 4. (emphasis added). Third, the Examiner states, “[n]or has Applicant provided any distinguishing characteristics regarding the effective use of glycolipids to treat HCV infection.” *Id.*

Applicants respectfully traverse the examiner’s rejection and maintain that subject matter of claims 12, 15-17, 20, 22-24 and 63-64 was described adequately in the

specification as filed so as to convey to one of skill in the art that the inventors had possession of the claimed invention.

Initially, Applicants note that claim 12 (and its dependent claims) are directed to “[a] process for treating a disease in a mammalian subject comprising administering to said subject an effective amount of an intermediary metabolite or a reagent that increases the intracellular or extracellular or serum level of a mammalian intermediary metabolite in said subject, wherein said intermediary metabolite or reagent is a glycolipid, and wherein said disease is cancer, a viral infection, or an autoimmune disease.” The specification, as filed, clearly supports this recitation of this process, *inter alia* at page 14, line 23 - page 15, line 1, which describes the administration of an effective amount of a mammalian intermediary metabolite or reagent, wherein such administration raises the subject’s intracellular or extracellular or serum level of the metabolite. The specification, as filed, elaborates, *e.g.*, on page 15, lines 1-5, that the intermediary metabolite may be a glycolipid, as claimed. Further, the specification *inter alia* at page 15, lines 6-9, describes various means of administration of the intermediary metabolite or reagent, including intravenous, intra-muscular, subcutaneous, intra-peritoneal or oral means. The specification *inter alia* at page 15, lines 10-16 and page 16, lines 1-2, also specifies that a viral infection such as HCV (the elected species of the present invention) is among several diseases which may be treated in accordance with the present invention.

The specification further notes at page 1, lines 2-11, that the provided processes for regulation or manipulation of the immune system alter the intracellular or serum levels of intermediate metabolites in a subject and that such manipulation or change in the immune system may be achieved ***directly or indirectly***. (emphasis added). The Examiner’s assertion at page 5 of the Office Action that “[a]pplicant has not performed any research or investigation to determine which immune component has to be changed via the administration of glycolipids to treat HCV” is misplaced, since the claims do not recite any change in immune components. The claims relate to “treatment by administering to a subject an effective amount of an intermediary metabolite or a reagent that increases the intracellular or extracellular or serum level of a mammalian intermediary metabolite in said subject,” **not** to a method of manipulation or change in a ***particular*** immune system component, which itself may alter the intracellular or serum

levels of intermediate metabolites. The level of detail required by the Examiner is beyond the scope of the claims, which do not recite an underlying mechanism for the increased level of the mammalian intermediary metabolite or reagent.

The specification at page 7, lines 7-9, describes that “[d]irect means [of altering the intracellular or serum levels of intermediate metabolites] can include introduction of the metabolite into the subject” -- the direct means (of administration), as recited by the claims.<sup>1</sup> In addition, the specification describes that “[e]ffective amounts of the [intermediary] metabolite or reagent introduced into the cells ... should depend upon the individual pharmacokinetic properties of said compounds [*i.e.*, the intermediary metabolite or reagent] to achieve sufficient levels of said metabolite in said subject for the duration desired.” See Specification, page 13, lines 16-19.

Moreover, the specification describes that intermediary metabolites, such as glucosylceramides, may be administered to a subject “such that one component of the immune system is elevated to such an extent that a specific activation of the NKT cell population [a particular component of the immune system] is effected.” See, *e.g.*, page 13, line 23 – page 14, line 5. Applicants submit that the specification provides evidence that specific immune parameters are modulated in response to a metabolite, such as a glycolipid. For example, Figures 1-6 illustrate the results of assays leading to T-cell proliferation and changes in IFN $\gamma$  serum levels, IL-4 serum levels, IL-10 serum levels and peripheral NKT lymphocytes. Thus, Applicants maintain that the specification, as filed, provides a written description for one of skill in the art as to types of immune parameter or marker which may be gauged upon administration of a glycolipid when that particular immune response is part of the pathogenesis of a disease, *e.g.*, T-cells, IFN-gamma, IL-4, IL-10 and peripheral NKT lymphocytes. Therefore, the Examiner’s assertion of no investigation having been provided by Applicants as to which immune component has to be changed by glycolipid administration is incorrect.

---

<sup>1</sup> The specification at page 8, lines 2-13, also describes **indirect** ways to achieve such elevated levels of metabolites, however, these methods do not involve administration of an intermediary metabolite or a reagent that increases the intracellular or extracellular or serum level of a mammalian intermediary metabolite in a subject, as claimed.

As noted above, however, the Examiner's requirement that such specific immune component change be shown is misplaced, since the pending claims are directed to a process for treating a disease so as to thereby increase the levels of mammalian intermediary metabolite or reagent, such as a glycolipid. The claims do **not** recite a method of manipulation or change in a *particular* immune system component, which itself may alter the intracellular or serum levels of intermediate metabolites. Accordingly, the level of detail required by the Examiner, *i.e.*, the immune component change, is beyond the scope of the claims, which do not recite an underlying mechanism for the increased level of the mammalian intermediary metabolite or reagent.

Finally, Applicants wish to direct the Examiner's attention to recent Federal Circuit case law which clarifies what is **not** required for an adequate written description. *Falkner v. Inglis*, 448 F.3d 1357, 1366 (Fed. Cir. 2006) held that "(1) **examples are not necessary to support the adequacy of a written description** (2) **the written description standard may be met even where actual reduction to practice of an invention is absent**; and (3) **there is no per se rule that an adequate written description of an invention that involves a biological macromolecule must contain a recitation of known structure.**" (emphasis added).

The Inglis application was directed to poxvirus, but did not contain examples involving the poxviruses. *Id.* The Federal Circuit reiterated that a claim will not be invalidated because the embodiments of the specification do not contain examples explicitly covering the full scope of the claim language "because the patent specification is written for a person of skill in the art, and as such a person comes to the patent with the knowledge of what has come before" and "in that context, it is unnecessary to spell out every detail of the invention in the specification..." *Id.* (citing *LizardTech, Inc. v. Earth Resource Mapping, PTY, Inc.*, 424 F.3d 1336, 1345 (Fed. Cir. 2005) (internal citations omitted)).

The Federal Circuit cited its explanation in *Capon v. Eshar* that "[t]he 'written description' requirement implements the principle that a patent must describe a technology that is sought to be patented; the requirement serves both to satisfy the inventor's obligation to disclose the technologic knowledge upon which the patent is based, and to demonstrate that the patentee was in possession of the invention that is



claimed.” 418 F.3d 1349, 1357 (Fed. Cir. 2005). Thus, the fact that “Inglis had not actually produced a poxvirus vaccine” was not dispositive, “because an actual reduction to practice is not required for written description.” *Id.* at 1366 (citing *Univ. of Rochester v. G.D. Searle & Co.*, 358 F.3d 916, 926 (Fed. Cir. 2004) (not suggesting that written description can be satisfied only by providing an actual reduction to practice and stating that constructive reduction to practice is an established method of disclosure). *Id.* at 1367. An “‘invention’ must refer to a concept that is complete, rather than merely one that is ‘substantially complete.’” *Id.* (citing *Pfaff v. Wells Elecs.*, 525 U.S. 55,66 (1998)).

Accordingly, the Examiner’s requirement for the written description requirement at page 5 of the Office Action that (1) the specification provide[s] ... “evidence relating to the effective use of glycolipids to treat HCV infection” and that “Applicant [must] ... characterize[] the effect of glycolipids in subjects that are infected with HCV” runs contrary to the *Falkner* holding that examples are not necessary to support the adequacy of a written description. *Falkner*, 448 F.3d at 366.

Second, the Examiner’s statement at page 4 of the Office Action that “the specification does not contain a description of actual reduction to practice that glycolipids are effective in treating HCV infection” clearly runs contrary to the *Falkner* holding that “the written description standard may be met even where actual reduction to practice of an invention is absent.” *Falkner*, 448 F.3d at 366.

Third. Applicant has provided a constructive reduction to practice, which is an established method of disclosure for written description. Thus, the Examiner’s assertions at page 4 that “Applicant has not shown that the invention was ‘ready for patenting’ by disclosing drawings demonstrating that glycolipids are effective in treating HCV” and not “provided any distinguishing characteristics regarding the effective use of glycolipids to treat HCV infection” constructive reduction to practice is an established method of disclosure are erroneous.

Lastly, the Examiner misconstrues the methods of the present invention with the conclusion at page 5 of the Office Action that an HCV infection would resolve itself in a Gaucher patient. The present invention provides for amelioration of symptoms. Applicant’s invention has never been described as a cure for this disease.

For these reasons, Applicants submit that the claimed process for “treating a disease in a mammalian subject comprising administering to said subject an effective amount of an intermediary metabolite or a reagent that increases the intracellular or extracellular or serum level of a mammalian intermediary metabolite in said subject” is sufficiently described by the specification as filed for a person of skill in the art. Therefore, Applicants respectfully request reconsideration and withdrawal of the rejection of claims 12, 15-17, 20, 22-24 and 63-64 under 35 U.S.C. § 112, first paragraph for lack of written description.

***Reply to Rejection Under 35 U.S.C. § 112, ¶ 1, Enablement***

Claims 12, 15-17, 20, 22-24 and 63-64 were rejected under 35 U.S.C. § 112, ¶ 1 as allegedly failing to comply with the enablement requirement of 35 U.S.C. § 112, ¶ 1.

In considering the *Wands* factor of the nature of the invention is whether the specification would require undue experimentation by one of skill in the art, the Examiner at page 7 states, that the “claimed invention is directed at the treatment of diseases, wherein the elected disease is hepatitis C virus, HCV, with the administration of a glycolipid” and that “the claimed invention relates to the application of glycolipid to regulate and manipulate immune responses, Th1 and Th2 responses, in mammalian subjects...”

With respect to the *Wands* factor of the breadth of the claims, the Examiner at page 7 states that the claims encompass all diseases....”

Regarding the *Wands* factor of presence or absence of working examples, the Examiner at pages 7-8 avers that “[t]he specification does not contain any working examples demonstrating the effective use of glycolipids to treat HCV infection” and that “Applicant has not set forth any guidance or direction relating to the immune component that must be changed or modulated in order to render treatment to HCV infected subjects.”

As to the *Wands* factor of the state of the art, the Examiner at page 8 states that “[t]he hepatitis C virus (HCV) art clearly notes that the role of innate and antigen-nonspecific response to HCV has not yet been sufficiently characterized” and that in such

absence, “the skilled artisan would not readily be able to practice the claimed invention without an undue burden of experimentation.” It should be noted that the present invention does not depend upon a characterization of the mechanism by which an immune response to HCV contributes to the pathogenesis of the disease and only seeks to reduce the effects caused by this response. The Examiner asserts at pages 8-9 that several factors challenge the development of an effective treatment for HCV, including 1) the lack of an effective cell culture system, 2) “the absence of good animal models, outside of humans and chimpanzees,” and 3) “the ability of HCV to evade effective immune recognition, including recognition by cytotoxic T lymphocytes (CTL) and shows an extremely high rate of viral persistence.” The Examiner further asserts that the last enumerated factor “establishes that the type of experimentation that the skilled artisan would have to perform ... is beyond routine experimentation, such as establishing route of administration and treatment dosage amounts.” See Office Action, page 9.

Regarding the *Wands* factor of quantity of experimentation necessary, the Examiner states on page 10 that “[i]n order to practice the claimed invention, the skilled artisan would have to blindly and unduly experiment with glycolipids, each immune component and determine the relationship among the glycolipids, each immune component and HCV infection.” While the specification discloses that the dosage effects of a glycolipid on one or more immune properties would be known to be associated with a disease (such as HCV), the Examiner seems to believe that there would be a further requirement for establishing the exact relationship (mechanism) between glycolipids, immune components and HCV. While this research into the mechanism would certainly be of continued interest to a researcher, it is not required for the practice of the present invention.

Applicants respectfully disagree and traverse this rejection and maintain that the specification offers adequate guidance to those skilled in the art to practice the claimed process of claims 12, 15-17, 20, 22-24 and 63-64.

It is well established under 35 U.S.C. §112 ¶ 1, that, “[t]he test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is *undue*.” MPEP 2164.01 (citing *In re Angstadt*, 537 F.2d 498, 504, 190 USPQ 214, 219 (CCPA 1976) (Emphasis added)). Applicants maintain that the

specification provides sufficient guidance to enable one skilled in the art to administer a an effective amount of an intermediary metabolite or a reagent, such as a glycolipid, to increase the intracellular or extracellular or serum level of a mammalian intermediary metabolite in said subject, as claimed.

Applicants address the *Wands* factor in turn.

#### Nature of the Invention

As discussed above in the discussion of written description, claim 12 and its dependent claims relate to “treatment by administering to a subject an effective amount of an intermediary metabolite or a reagent that increases the intracellular or extracellular or serum level of a mammalian intermediary metabolite in said subject,” **not** to a method of manipulation or change in a *particular* immune system component, which itself may alter the intracellular or serum levels of intermediate metabolites. The specification, as filed, provides, *e.g.*, on page 15, lines 1-5, that the intermediary metabolite may be a glycolipid, as claimed.

Thus, Examiner’s statement that the invention relates to regulation and manipulation of immune responses and Th1 and Th2 responses is attempting to insert into the claims a possible underlying mechanisms of increasing intracellular or extracellular or serum level of a mammalian intermediary metabolite, however, no such mechanism is specifically recited in the pending claims. Thus, the assertion extends beyond the scope of the **claimed** invention.

#### Breadth of the Claims

Applicants maintain that the Examiner’s assertion that the “claims encompass all diseases ... “ is over-inclusive. In fact, the claim 12 recites diseases such as cancer, a viral infection or an autoimmune disease. HCV is the elected species of a viral infection of the present invention.

#### Presence or Absence of Working Examples

As noted above, the Examiner’s requirement of examples of or guidance for which immune component must be changed or modulated in order to render treatment to

HCV infected subjects is misplaced. The claims are directed to a process for treating a disease, **not** to a method of manipulation or change in a *particular* immune system component, which itself may alter the intracellular or serum levels of intermediate metabolites.

The specification at page 7, lines 7-9, describes that “[d]irect means [of altering the intracellular or serum levels of intermediate metabolites] can include introduction of the metabolite into the subject” -- the direct means (of administration), as recited by the claims. In addition, the specification describes that “[e]ffective amounts of the [intermediary] metabolite or reagent introduced into the cells ... should depend upon the individual pharmacokinetic properties of said compounds [*i.e.*, the intermediary metabolite or reagent] to achieve sufficient levels of said metabolite in said subject for the duration desired.” See Specification, page 13, lines 16-19.

Further, the specification *inter alia* at page 15, lines 6-9, describes various means of administration of the intermediary metabolite or reagent, including intravenous, intramuscular, subcutaneous, intra-peritoneal or oral means. The specification *inter alia* at page 15, lines 10-16 and page 16, lines 1-2, also specifies that a viral infection such as HCV (the elected species of the present invention) is among several diseases which may be treated in accordance with the present invention.

Applicants note that the level of skill of the relevant artisan is high, *e.g.*, a person having an advanced degree (doctorate or medical degree) in immunology or infectious disease and the like.

Moreover, as the Federal Circuit held in *Falkner*, a claim will not be invalidated because the embodiments of the specification do not contain examples explicitly covering the full scope of the claim language “because the patent specification is written for a person of skill in the art, and as such a person comes to the patent with the knowledge of what has come before” and “in that context, it is unnecessary to spell out every detail of the invention in the specification...” *Id.* (citing *LizardTech, Inc. v. Earth Resource Mapping, PTY, Inc.*, 424 F.3d 1336, 1345 (Fed. Cir. 2005) (internal citations omitted)). See also MPEP § 2164.02. (the absence of working examples will not by itself render the invention non-enabled.)

In light of the above discussion, it is clear that the specification sufficiently guides one of skill in the art so as to enable the skilled artisan to administer an effective amount of an intermediary metabolite or a reagent, such as a glycolipid, to increase the intracellular or extracellular or serum level of a mammalian intermediary metabolite in said subject, as claimed.

#### State of the Art

The claims are directed to a process for treating a disease, **not** to a method of manipulation or change in a *particular* immune system component, which itself may alter the intracellular or serum levels of intermediate metabolites. Therefore, the presently pending claims do not recite a mechanism for a specified “role of innate and antigen-nonspecific response to HCV” or to any specific immune component that is changed upon administration of a mammalian intermediary metabolite or reagent, such as a glycolipid. The Examiner improperly appears to require elucidation of an underlying mechanism for the claimed treatment. The test under 35 U.S.C. §112 ¶ 1, is not “whether any experimentation is necessary, but whether, if experimentation is necessary, it is *undue*.” MPEP 2164.01 (citing *In re Angstadt*, 537 F.2d 498, 504, 190 USPQ 214, 219 (CCPA 1976) (Emphasis added)).

Applicants maintain that the specification provides sufficient guidance to enable one skilled in the art to practice the claimed process for treating a disease, such as HCV, by administering an effective amount of an intermediary metabolite or a reagent, such as a glycolipid, to increase the intracellular or extracellular or serum levels of the intermediary metabolite or a reagent.

The specification teaches one of skill that intermediary metabolites, such as glucosylceramides, may be administered to a subject “such that one component of the immune system is elevated to such an extent that a specific activation of the NKT cell population [a particular component of the immune system] is effected.” *See, e.g.*, page 13, line 23 – page 14, line 5. Applicants submit that the specification provides adequate guidance as to specific immune parameters that may be modulated in response to the administration of a intermediary metabolite, such as a glycolipid. For example, Figures 1-6 illustrate the results of assays leading to T-cell proliferation and changes in IFN $\gamma$

serum levels, IL-4 serum levels, IL-10 serum levels and peripheral NKT lymphocytes. Accordingly, one of skill in the art is guided as to types of immune parameter or marker which may be gauged upon administration of a glycolipid when that particular immune response is part of the pathogenesis of a disease, *e.g.*, T-cells, IFN-gamma, IL-4, IL-10 and peripheral NKT lymphocytes.

Additionally, the specification provides as follows:

These assays and figures demonstrate that the presence of an increased level of a metabolite has led to significant changes in the immune profile of these subjects. Surprisingly, when this condition was accompanied by another immune system challenge (HCV infection), there was significant impact on the immune profile of the HCV + subjects compared to the subjects that lacked elevation of the metabolite.

*See* Specification at page 12, first full paragraph.

Applicants, again reiterate, that the claims are directed to a method of treatment of a disease by administering an intermediary metabolite or reagent, and do not specify an underlying mechanism of any particular immune component in the amelioration of the disease. Thus, Applicants maintain that the specification, as filed, enables one of skill in the art how to practice the claimed invention without undue experimentation.

#### Quantity of Experimentation Necessary

Contrary to the Examiner's assertion that one of skill in the art cannot rely on the specification to reasonably practice the invention without undue experimentation, one of skill in the art is adequately guided and enabled to practice the claimed method of treatment of a disease such as HCV by administration of an intermediary metabolite or reagent, such as a glycolipid. The specification, as filed, provides an association between an increase in the intracellular or extracellular or serum level of a mammalian intermediary metabolite or reagent, such as a glycolipid, and the treatment of a disease, such as HCV.

Moreover, the specification clearly set forth a protocol for administering a mammalian intermediary metabolite or reagent to increase the intracellular or extracellular or serum level of the mammalian metabolite. The specification *inter alia* at

page 15, lines 6-9, describes various means of administration of the intermediary metabolite or reagent, including intravenous, intra-muscular, subcutaneous, intra-peritoneal or oral means.

The specification also describes that “[e]ffective amounts of the [intermediary] metabolite or reagent introduced into the cells ... should depend upon the individual pharmacokinetic properties of said compounds [*i.e.*, the intermediary metabolite or reagent] to achieve sufficient levels of said metabolite in said subject for the duration desired.” See Specification, page 13, lines 16-19.

Given the high level of skill in the art, the breadth of the claims, the amount of direction and guidance presented in the specification -- such that experimentation by one of skill in the art is not undue, the presently pending claims are fully enabled by the specification as filed.

For the reasons above, Applicants respectfully submit that the pending claims are enabled by the instant specification, and as such, a skilled artisan is sufficiently guided to make and use the claimed invention commensurate with the scope of the presently amended claims without undue experimentation. Applicant respectfully requests reconsideration and withdrawal of this rejection of claims 12, 15-17, 20, 22-24 and 63-64 under 35 U.S.C. § 112, first paragraph for lack of enablement.

In view of at least the foregoing, Applicants respectfully submit that the claims are in condition for allowance.



**CONCLUSION**

Early notification of a favorable consideration is respectfully requested. The Examiner is respectfully requested to contact the undersigned by telephone at the below listed telephone number, in order to expedite resolution of any issues and to expedite passage of the present application to issue, if any comments, questions, or suggestions arise in connection with the present application.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: Feb. 20, 2008

By: Kellie L. Carden  
Robert M. Schulman  
Registration No. 31,196  
Kellie L. Carden  
Registration No. 52,696

HUNTON & WILLIAMS LLP  
Intellectual Property Department  
1900 K Street, N.W., Suite 1200  
Washington, DC 20006-1109  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)